Molecular epidemiology of serotype 19A Streptococcus pneumoniae among invasive isolates from Alaska, 1986-2010

International Journal of Circumpolar Health

Volumn 72, Issue SUPPL.1, 2013, Pages

  Rudolph, Karen ^a   Bruce, M G ^a   Bulkow, L ^a   Zulz, T ^a   Reasonover, A ^a   Harker Jones, M ^a   Hurlburt, D ^a   Hennessy, T W ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Alaska; Invasive disease; MLST; Serotype 19A; Streptococcus pneumoniae

Indexed keywords

ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGE; ANTIBIOTIC RESISTANCE; ARTICLE; CHILD; DRUG EFFECT; GENETICS; HUMAN; INCIDENCE; INVASIVE DISEASE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MLST; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; SEROTYPE 19A; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; YOUNG ADULT;

ALASKA; INVASIVE DISEASE; MLST; SEROTYPE 19A; STREPTOCOCCUS PNEUMONIAE;

ADOLESCENT; ADULT; AGE FACTORS; ALASKA; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; HUMANS; INCIDENCE; MICROBIAL SENSITIVITY TESTS; MOLECULAR EPIDEMIOLOGY; MULTILOCUS SEQUENCE TYPING; PNEUMOCOCCAL INFECTIONS; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 84881297374     PISSN: 12399736     EISSN: 22423982     Source Type: Journal    
DOI: 10.3402/ijch.v72i0.20854     Document Type: Article

References (35)

1. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737-46.
2. Kaplan SL, Mason EO Jr., Wald ER, Schutze GE, Bradley JS, Tan TQ, et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics. 2004;113:443-9.
3. Lexau CA, Lynfield R, Danila R, Pilishvili T, Facklam R, Farley MM, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043-51.
4. Hicks L, Harrison L, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to nonpneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis. 2007;196:1346-54.
5. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B. Post-vaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192:1988-95.
6. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenbery J, et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007;26:468-72.
7. Moore MR, Gertz RE, Woodbury RL, Barkocy-Gallagher GA, Schaffner W, Lexau C, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis. 2008;197:1016-27.
8. Messina AF, Katz-Gaynor K, Barton T, Ahmad N, Ghaffar F, Rasko D, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr Infect Dis J. 2007; 26:461-7.
9. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, Hurlburt DA, et al. Invasive pneumococcal disease caused by non-vaccine serotype among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA. 2007;297:1784-92.
10. Centers for Disease Control and Prevention. Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae-Massachusetts, 2001-2006. MMWR Morb Mortal Wkly Rep. 2007;56:1077-80.
11. Davidson M, Parkinson AJ, Bulkow LR, Fitzgerald MA, Peters HV, Parks DJ. The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990-ethnic differences and opportunities for prevention. J Infect Dis. 1994;170:368-76.
12. Rudolph KM, Parkinson AJ, Reasonover AL, Bulkow LR, Parks DJ, Butler JC. Serotype distribution and antimicrobial resistance patterns of invasive isolates of Streptococcus pneumoniae: Alaska, 1991-1998. J Infect Dis. 2000;182:490-6.
13. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 15th Informational Supplement. Wayne, PA: Clinical and Laboratory Standards Institute, 2007. Approved standard M100-S17.
14. Sutcliffe J, Grebe T, Tait-Kamradt A, Wondrack L. Detection of erythromycin resistant determinants by PCR. Antimicrob Agents Chemother. 1996;40:2562-6.
15. Tait-Kamradt A, Clancy J, Cronan M, Dib-Hajj F, Wondrack L, Yuan W, et al. mefE is necessary for the erythromycinresistant M phenotype in Streptococcus pneumoniae. Antimicrob Agents Chemother. 1997;41:2251-5.
16. Montanari MP, Mingoia M, Cochetti I, Varaldo PE. Phenotypes and genotypes of erythromycin-resistant pneumococci in Italy. J Clin Micro. 2003;41:428-31.
17. Enright MC, Spratt BG. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology. 1998;144: 3049-60.
18. Hennessy TW, Singleton RJ, Bulkow LR, Bruden DL, Hurlburt DA, Parks D, et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine. 2005;23: 5464-73.
19. Beall B, McEllistrem MC, Gertz RE Jr., Wedel S, Boxrud DJ, Gonzalez AL, et al. Pre-and postvaccination clonal compositions of invasive pneumococcal serotypes of isolates collected in the United States in 1999, 2001, and 2002. J Clin Micro. 2006;44:999-1017.
20. Pillai DR, Shahinas D, Buzina A, Pollock RA, Lau R, Khairnar K, et al. Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae. BMC Genomics. 2009;10:642-55.
21. Hanage WP, Bishop CJ, Lee GM, Lipsitch M, Stevenson A, Rifas-Shiman SL, et al. Clonal replacement among 19A Streptococcus pneumoniae in Massachusetts, prior to 13 valent conjugate vaccination. Vaccine. 2011;29:8877-81.
22. Mahjoub-Messai F, Doit C, Koeck J, Billard T, Evrard B, Bidet P, et al. Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal vaccination for French children. J Clin Microbiol. 2009;47:837-40.
23. Muñoz-Almagro C, Esteva C, de Sevilla M, Selva L, Gene A, Pallares R. Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. J Infect. 2009;59:75-82.
24. Vestrheim DF, Steinbakk M, Aaberge IS, Caugant DA. Postvaccination increase in serotype 19A pneumococcal disease in Norway is driven by expansion of penicillin-susceptible strains of the ST199 complex. Clin Vaccine Immunol. 2012; 19:443-5.
25. van Deursen AMM, van Mens SP, Sanders EAM, Vlaminckx BJM, de Melker HE, Schouls LM, et al. Invasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands. Emerg Infect Dis. 2012;18:1729-37.
26. Clarke SC, Scott KJ, McChlery SM. Serotypes and sequence types of pneumococci causing invasive disease in Scotland prior to the introduction of pneumococcal conjugate polysaccharide vaccines. J Clin Micro. 2004;42:4449-52.
27. Scott JR, Hanage WP, Lipsitch M, Millar EV, Moulton LH, Hinds J, et al. Pneumococcal sequence type replacement among American Indian children: a comparison of pre-and routine-PCV7 eras. Vaccine. 2012;30:2376-81.
28. Beall BW, Gertz RE, Hulkower RL, Whitney CG, Moore MR, Brueggemann AB. Shifting genetic structure of invasive serotype 19A pneumococci in the United States. J Infect Dis. 2011;203:1360-8.
29. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19 A clones that cause acute otitis media in an unvaccinated population. J Infect Dis. 2009;199:776-85.
30. Porat N, Benisty R, Trefler R, Givon-Lavi N, Dagan R. Clonal distribution of common pneumococcal serotypes not included in the 7-valent conjugate vaccine (PCV7): marked differences between two ethnic populations in southern Israel. J Clin Microbiol. 2012;50:3472-7.
31. Tarragó D, Aguilar L, Garci{dotless}́a R, Gimenez M, Granizo J, Fenoll A. Evolution of clonal and susceptibility profiles of serotype 19A Streptococcus pneumoniae among invasive isolates from children in Spain, 1990 to 2008. Antimicrob Agents Chemo. 2011;55:2297-302.
32. Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Liñares J. Emergence of a multidrug resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J Antimicrob Chemother. 2009;64:507-10.
33. Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee J, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis. 2008;14:275-81.
34. Bruce M, Wenger J, Zulz T, Singleton R, Bulkow L, Rudolph K, et al. Invasive pneumococcal disease (IPD) in Alaska children: impact of the 13-valent pneumococcal conjugate vaccine (PCV13). Presented at 8th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD), Iguacu Falls, Brazil, 2012.
35. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354:1455-63.